These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 19509168

  • 1. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.
    Clin Cancer Res; 2009 Jun 15; 15(12):4038-45. PubMed ID: 19509168
    [Abstract] [Full Text] [Related]

  • 2. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.
    Clin Cancer Res; 2011 Oct 15; 17(20):6448-58. PubMed ID: 22003072
    [Abstract] [Full Text] [Related]

  • 3. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 15; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, Blanc V, Lambert JM.
    Mol Pharm; 2015 Jun 01; 12(6):1703-16. PubMed ID: 25856201
    [Abstract] [Full Text] [Related]

  • 6. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 7. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM.
    Clin Cancer Res; 1998 May 01; 4(5):1305-14. PubMed ID: 9607591
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW.
    Clin Cancer Res; 2005 Jul 01; 11(13):4857-66. PubMed ID: 16000584
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
    Horváth B, Demeter J, Eros N, Hársing J, Csomor J, Matolcsy A, Bottlik G, Gyori G, Marschalkó M, Kárpáti S.
    J Am Acad Dermatol; 2009 Nov 01; 61(5):885-8. PubMed ID: 19632742
    [Abstract] [Full Text] [Related]

  • 17. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
    Manolopoulos L, Gomatos IP, Leandros E, Alevizos L, Georgiou N, Giotakis J, Ferekidis E.
    In Vivo; 2009 Nov 01; 23(3):475-8. PubMed ID: 19454517
    [Abstract] [Full Text] [Related]

  • 18. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B, Santos ES.
    Expert Rev Anticancer Ther; 2007 Mar 01; 7(3):257-73. PubMed ID: 17338647
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
    Malliti M, Junot H, Fievet MH, Gabarre J, Taright N, Vernant JP, Thuillier A.
    Ann Med Interne (Paris); 2003 May 01; 154(3):139-47. PubMed ID: 12910040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.